The U.S. Food and Drug Administration (FDA) on Tuesday issued a stark warning to patients and healthcare providers about the dangers of unapproved and compounded GLP-1 weight-loss medications. If you've been tempted to buy semaglutide or tirzepatide from an online seller that isn't a licensed pharmacy, this one's for you.
The agency says consumers are increasingly running into illegally marketed versions of these drugs, often sold by shady online outfits. The risks? Unsafe chemical formulations, incorrect dosing, and contamination. Not exactly what you want when you're trying to get healthier.
The market took notice. Hims & Hers Health Inc. (HIMS), a telehealth company that has jumped into the weight-loss space, saw its stock close 3.85% lower on Tuesday after the FDA's announcement.
Rising Adverse Events And Dosing Hazards
The FDA's concerns aren't theoretical. As of May 31, 2026, the agency had received 990 adverse event reports related to compounded semaglutide and over 730 reports involving compounded tirzepatide. These aren't just minor complaints. Patients have reported hospitalizations, severe gastrointestinal symptoms like nausea and vomiting, and injection site reactions from these fraudulent formulations.
For context, tirzepatide is the active ingredient in Eli Lilly and Co.'s (LLY) Zepbound and Mounjaro, while semaglutide is what makes Novo Nordisk A/S's (NVO) Ozempic and Wegovy work. These are powerful prescription drugs, and when they're not made properly, they can cause real harm.
One particular problem: compounders are illegally using unapproved salt forms of these drugs, such as semaglutide sodium and semaglutide acetate. These aren't the same as the FDA-approved versions, and they haven't been proven safe or effective.
There's also the contamination risk. Patients using multi-dose vials beyond 28 days or receiving shipments that weren't properly refrigerated are playing with fire. These drugs need to be handled carefully, and when they're not, you're rolling the dice.
Federal Crackdown On Illegal Distribution
The FDA isn't just issuing warnings; it's taking action. Federal law strictly bans the use of Eli Lilly's retatrutide and Novo Nordisk's cagrilintide in drug compounding. Regulators have sent warning letters to active pharmaceutical ingredient distributors, outsourcing facilities, and telehealth vendors who are marketing unauthorized drugs, including products falsely labeled "for research purposes" or "not for human consumption."
To keep poor-quality foreign ingredients from sneaking into the U.S. supply chain, the agency has implemented import alert 66-80. This targets non-compliant manufacturers while still allowing compliant imports to flow. It's a way to choke off the bad stuff without disrupting the legitimate market.
As for Hims & Hers, the stock was down another 0.56% in premarket trading Wednesday, sitting at $28.28. The company has been expanding its weight-loss offerings, but this FDA warning is a reminder that the regulatory environment around compounded GLP-1s is getting tougher.
So, what's the takeaway? If you're considering a GLP-1 drug for weight loss, make sure you're getting it from a legitimate source. That means a prescription from a licensed healthcare provider and a pharmacy that follows FDA regulations. Buying from random websites or social media ads is a gamble with your health, and the odds aren't in your favor.
